Trandolapril
Alternative Names: Gopten; Mavik; Nortensin; Odrik; Preran; RU 44570Latest Information Update: 23 Dec 2021
At a glance
- Originator sanofi-aventis
- Class Antihypertensives; Indoles
- Mechanism of Action ACE inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Heart failure; Hypertension; Postmyocardial infarction
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
- 03 Jun 2004 Aventis granted Abbott Laboratories the remaining commercial rights for trandolapril, except in Japan
- 19 Mar 2004 Data presented at the 53rd Annual Scientific Sessions of the American College of Cardiology (ACC-2004) have been added to the Heart Failure and Ischaemic Heart Disease therapeutic trials sections